On February 3, 2025, Bioton S.A. – a Polish biotechnology company listed on the Warsaw Stock Exchange (GPW) — hosted a significant event for the Polish economy and pharmaceutical industry: a study visit by delegates from EU member states and representatives of the European Commission. The meeting, initiated by the Ministry of Development and Technology, took place on the eve of a joint session of EU ministers responsible for industry, the internal market, and trade. This session is part of the official calendar of events accompanying Poland’s Presidency of the EU Council. The guests were welcomed by the Secretary of State at the Chancellery of the Prime Minister, Minister Ignacy Niemczycki.
“Biotechnology and biomanufacturing are fundamental to addressing social and environmental challenges. However, this vital sector faces numerous obstacles, similar to those encountered by other key EU industries — ranging from regulatory complexity and access to financing to supply chain disruptions and intellectual property concerns. Therefore, we must intensify our efforts to strengthen the sector and enhance Europe’s technological self-sufficiency in this field,” said Deputy Minister Ignacy Niemczycki in his opening remarks.
The EU ministers and delegates toured Bioton’s state-of-the-art biopharmaceutical production facility in Macierzysz, near Warsaw. For 25 years, this site has been manufacturing recombinant human insulin — from biosynthesis of the active substance to the final pharmaceutical product. Bioton S.A. has long played a crucial role in ensuring pharmaceutical security and stabilizing public payer expenditures in the field of diabetes treatment. The company provides Polish patients with safe and comprehensive solutions for diabetes management.
In his speech, Jeremy Launders, CEO of Bioton S.A., emphasized:
“Bioton possesses both API and finished product manufacturing capabilities that can fully meet the demand for human insulin in Poland and across the European Union. Given the risk of shortages in the supply of human insulin — a life-saving medication included on the EU list of critical medicines — Bioton’s production of insulin API and finished products can significantly contribute to pharmaceutical security at both national and European levels.”
The event was also attended by Dr. Magdalena Kulczycka, President of the Association of Biotechnology Companies, BioForum, who highlighted that biotechnology is one of the pillars of Europe’s competitiveness, as recognized in the STEP program and the Draghi Report. She stressed that “A constructive dialogue between companies and regulators, which lays the foundation for the European ecosystem, is key to achieving Europe’s competitiveness.”
In conclusion, Bioton’s activities align with the European Commission’s strategy to reduce the EU’s dependence on non-European sources of active pharmaceutical ingredients (APIs) and medicines, while strengthening the EU’s global competitiveness. Bioton S.A.’s products are registered in over 30 countries worldwide, and the company’s strategy focuses on expanding access to high-quality biological medicines manufactured in Poland for patients requiring insulin treatment across the globe.
